Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Arch Physiol Biochem ; 118(3): 148-55, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22515179

ABSTRACT

The insulin receptor (IR) recruits adaptor proteins, so-called insulin receptor substrates (IRS), to connect with downstream signalling pathways. A family of IRS proteins was defined based on three major common structural elements: Amino-terminal PH and PTB domains that mediate protein-lipid or protein-protein interactions, mostly carboxy-terminal multiple tyrosine residues that serve as binding sites for proteins that contain one or more SH2 domains and serine/threonine-rich regions which may be recognized by negative regulators of insulin action. The current model for the role of IRS proteins therefore combines an adaptor function with the integration of mostly negative input from other signal transduction cascades allowing for modulation of signalling amplitude. In this review we propose an extended version of the adaptor model that can explain how signalling specificity could be implemented at the level of IRS proteins.


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Insulin Receptor Substrate Proteins/metabolism , Receptor, Insulin/metabolism , Signal Transduction/genetics , Animals , Binding Sites , Diabetes Mellitus, Type 2/genetics , Diabetes Mellitus, Type 2/physiopathology , Gene Expression Regulation , Humans , Insulin Receptor Substrate Proteins/genetics , Insulin Resistance/genetics , Models, Biological , Protein Binding , Protein Structure, Tertiary , Receptor, Insulin/genetics , Tyrosine/metabolism
2.
Vaccine ; 30(6): 989-94, 2012 Feb 01.
Article in English | MEDLINE | ID: mdl-22197965

ABSTRACT

In recent years the safety of the yellow fever live vaccine 17D came under scrutiny. The focus was on serious adverse events after vaccinations that resemble a wild type infection with yellow fever and whose reasons are still not known. Also the exact mechanism of attenuation of the vaccine remains unknown to this day. In this context, the standards of safety and surveillance in vaccine production and administration have been discussed. Therein embodied was the demand for improved documentation of the derivation of the seed virus used for yellow fever vaccine production. So far, there was just a historical genealogy available that is based on source area and passage level. However, there is a need for a documentation based on molecular information to get better insights into the mechanisms of pathology. In this work we sequenced the whole genome of different passages of the YFV-17D strain used by Crucell Switzerland AG for vaccine production. Using all other publically available 17D full genome sequences we compared the sequence variance of all vaccine strains and oppose a phylogenetic tree based on full genome sequences to the historical genealogy.


Subject(s)
Phylogeny , Yellow Fever Vaccine/genetics , Yellow fever virus/classification , Yellow fever virus/genetics , Cluster Analysis , Genetic Variation , Humans , Molecular Sequence Data , RNA, Viral/genetics , Sequence Analysis, DNA , Sequence Homology , Switzerland
3.
Transfusion ; 47(10): 1765-74, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17880601

ABSTRACT

BACKGROUND: B19 virus (B19V) is a human pathogen frequently present in blood specimens. Transmission of the virus occurs mainly via the respiratory route, but it has also been shown to occur through the administration of contaminated plasma-derived products. Parvoviridae are highly resistant to physicochemical treatments; however, B19V is more vulnerable than the rest of parvoviruses. The molecular mechanism governing the inactivation of B19V and the reason for its higher vulnerability remain unknown. STUDY DESIGN AND METHODS: After inactivation of B19V by wet heat and low pH, the integrity of the viral capsid was examined by immunoprecipitation with two monoclonal antibodies directed to the N-terminal of VP1 and to a conformational epitope in VP2. The accessibility of the viral DNA was quantitatively analyzed by a hybridization-extension assay and by nuclease treatment. RESULTS: The integrity of the viral particles was maintained during the inactivation procedure; however, the capsids became totally depleted of viral DNA. The DNA-depleted capsids, although not infectious, were able to attach to target cells. Comparison studies with other members of the Parvoviridae family revealed a remarkable instability of B19V DNA in its encapsidated state. CONCLUSION: Inactivation of B19V by heat or low pH is not mediated by capsid disintegration but by the conversion of the infectious virions into DNA-depleted capsids. The high instability of the viral DNA in its encapsidated state is an exclusive feature of B19V, which explains its lower resistance to inactivation treatments.


Subject(s)
Erythema Infectiosum/prevention & control , Parvovirus B19, Human/genetics , Transfusion Reaction , Virus Inactivation , Capsid Proteins/genetics , Cell Line , DNA Primers , DNA, Viral/genetics , Erythema Infectiosum/transmission , Flow Cytometry , Hot Temperature , Humans , Hydrogen-Ion Concentration , Parvovirus B19, Human/isolation & purification , Parvovirus B19, Human/pathogenicity , Polymerase Chain Reaction
4.
Biologicals ; 35(1): 35-42, 2007 Mar.
Article in English | MEDLINE | ID: mdl-16581263

ABSTRACT

Patients with immunodeficiencies or some types of autoimmune diseases rely on a safe therapy with intravenous immunoglobulins (IVIGs) manufactured from human plasma, the only available source for this therapeutic. Since plasma is predisposed to contamination by a variety of blood-borne pathogens, ascertaining and ensuring the pathogen safety of plasma-derived therapeutics is a priority among manufacturers. State-of-the-art manufacturing processes provide a high safety standard by incorporating virus elimination procedures into the manufacturing process. Based on their mechanism these procedures are grouped into three classes: partitioning, inactivation, and virusfiltration.


Subject(s)
Autoimmune Diseases/therapy , Immunoglobulins, Intravenous/isolation & purification , Immunoglobulins, Intravenous/standards , Viruses/isolation & purification , Drug Contamination , Hot Temperature , Humans , Plasma/chemistry , Prion Diseases/prevention & control , Prions/isolation & purification , Severe Combined Immunodeficiency/therapy , Viral Load , Virus Inactivation
5.
J Gen Virol ; 87(Pt 12): 3567-3575, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17098972

ABSTRACT

Our understanding of the mechanism(s) of pathogenesis and persistence of vertebrate parvoviruses remains incomplete. With the recent availability of the complete genome sequences of human, rat and mouse, and the ability to search these sequences and to locate matches to exact genomic regions, further insight into the interaction of parvoviruses with their human and rodent hosts is possible. To determine the extent and nature of sequence identity between candidate parvoviruses and their respective hosts, blast searches of the genome sequences of adeno-associated virus, parvovirus B19, mouse parvovirus, the prototype strain and immunosuppressant variant of minute virus of mouse, Kilham rat virus and rat parvovirus were performed against the genome(s) of their respective hosts (human, rat and mouse) using the resources of the NCBI and the Celera Discovery System. Regions of identity and similarity were mapped to their precise location in their particular host genome. For each virus, between one and 12 identical regions were found. Each identical region was 17-26 nt and was generally found at multiple sites within the particular host genome. These identical regions were predominantly located in non-coding regions of particular host genes and in intergenic regions. The ontology of host genes in which identical regions were found for each of the nine virus-host interactions highlighted several pathways/processes, including the cytoskeleton, cell adhesion and Wnt signalling. Within each virus species, these homologous regions were highly conserved (100 % identity in 16 out of 23 alignments where more than one sequence was available). All of these aspects suggest a particular advantage to the viruses of the presence of these sequences.


Subject(s)
DNA, Viral/genetics , Genome, Viral , Parvovirus/genetics , Sequence Homology, Nucleic Acid , Animals , Cell Adhesion/genetics , Computational Biology , Cytoskeleton/genetics , DNA, Intergenic , Humans , Mice , Rats , Signal Transduction/genetics , Wnt Proteins/metabolism
7.
Clin Rev Allergy Immunol ; 29(3): 333-44, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16391410

ABSTRACT

Patients with immunodeficiencies or some types of autoimmune diseases are dependent on safe therapy with intravenous immunoglobulins. State-of-the-art manufacturing processes provide a high safety standard by incorporating virus elimination procedures into the manufacturing process. Based on their mechanism, these procedures are grouped into three classes: partitioning, inactivation, and removal based on size. Because of current socioeconomic and ecological changes, emerging pathogens continue to be expected. Such pathogens may spread very quickly because of increased intercontinental traffic. Severe acute respiratory syndrome-coronavirus and the West Nile virus are recent examples. Currently, it is not possible to predict the impact such a pathogen will have on blood safety because the capacity for a globally coordinated reaction to such a threat is also evolving. The worst-case scenario would be the emergence of a transmissible, small, nonenveloped virus in the blood donor population. Examples of small nonenveloped viruses, which change host and tissue tropism, are discussed, with focus on parvoviridae. Although today's immunoglobulins are safer than ever, in preparation for future challenges it is a high priority for the plasma industry to proactively investigate such viruses on a molecular and cellular level to identify their vulnerabilities.


Subject(s)
Consumer Product Safety/standards , Drug Contamination/prevention & control , Immunoglobulins, Intravenous , Virus Diseases/prevention & control , Virus Inactivation , Animals , Disease Transmission, Infectious , Humans , Virus Diseases/transmission
8.
Biologicals ; 32(2): 94-104, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15454188

ABSTRACT

Although intravenous immunoglobulins (IVIG) and other plasma therapeutics have had a relatively good safety record, improved methods for viral clearance are constantly being evaluated and incorporated into new manufacturing processes. Gamma irradiation has been used routinely to assure sterility of healthcare products and medical devices, but it has not been applied successfully as a viral inactivation method for biologics. We examine whether virucidal doses of gamma irradiation (50 kGy) can be delivered to a manufacturing intermediate form of IVIG, a fractionated plasma paste, with negligible effect on structural and functional integrity of purified IgG product. Immunoglobulins from paste were examined for radiation-induced damage by SDS-PAGE and ELISAs utilizing viral antigens specific for rubella, CMV and mumps. Fc domain integrity was assessed by immunoblotting, quantitatively comparing the binding of irradiated and non-irradiated materials to cell surface Fcgamma receptors, and by employing quantitative RT-PCR to study the kinetics of accumulation of mRNA for the immune modulatory cytokines IL-1alpha, IL-1beta, IL-4, IL-8, IFNgamma, and TNFalpha. The results demonstrate that Fab and Fc domains of IVIG remain essentially intact and functional after gamma irradiation to virucidal doses, suggesting that this method could be used to enhance the safety of IVIG products.


Subject(s)
Gamma Rays , Immunoglobulins, Intravenous/chemistry , Antigens/chemistry , Binding, Competitive , Cytokines/metabolism , Cytomegalovirus/immunology , DNA Primers/chemistry , Dose-Response Relationship, Drug , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Fluorescein/chemistry , Humans , Immunoglobulin Fragments/chemistry , Immunoglobulin G/chemistry , Interleukin-4/metabolism , Kinetics , Mumps virus/immunology , Pharmaceutical Preparations , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Rubella virus/immunology , Sterilization , Tryptophan/chemistry
9.
Transfusion ; 44(7): 1079-86, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15225251

ABSTRACT

BACKGROUND: Parvoviridae are small nonenveloped viruses that are known to be highly resistant to physico-chemical treatments. Because low pH is frequently applied to process intermediates or final products, the impact of such conditions on the human erythrovirus B19 (B19V) and the mouse parvovirus (mice minute virus, MMV) was assessed, which is often used as a model for B19V. Owing to the lack of a suitable cultivation and/or detection system for B19V no such data exist so far. STUDY DESIGN AND METHODS: Virus inactivation was monitored by decrease of infectivity and loss of capsid integrity. Infectious B19V was quantified by detection of virus-specific messenger RNA from Ku812Ep6 cells. To measure capsid integrity, endonucleases were added after exposure to low pH and the encapsidated (endonuclease-protected) virus DNA was quantified by real-time PCR. RESULTS: B19V was inactivated greater than 5 log after 2 hours at pH 4, whereas MMV was resistant over 9 hours. Infectivity data strongly correlated with data obtained by the endonuclease assay. Capsid disintegration was observed in immunoglobulin G as well as in different albumin solutions. Temperature and pH showed concerted impact on B19V capsid disintegration. CONCLUSION: Our data show that B19V is much more vulnerable toward low pH conditions than MMV. Together with the previously reported susceptibility of B19V toward wet heat conditions, low pH is the second treatment where erythrovirus B19V is less resistant than viruses from the parvovirus genus.


Subject(s)
Minute Virus of Mice/physiology , Parvovirus B19, Human/physiology , Virus Inactivation , Animals , Capsid/metabolism , DNA, Single-Stranded/metabolism , DNA, Viral/metabolism , Humans , Hydrogen-Ion Concentration , Mice
10.
Biologicals ; 31(3): 181-5, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12935806

ABSTRACT

Treatment with steam and/or dilute NaOH are commonly used techniques to disinfect manufacturing vessels and tools in the pharmaceutical industry. The aim of this procedure is sanitisation and inactivation of microbiological and viral contaminants. Here we describe the inactivation of the mouse parvovirus Minute Virus of Mice (MVM) under these conditions. Parvoviruses are known to be resistant to physico-chemical treatment and one representative of this family, the human parvovirus B19, is a potential contaminant of blood plasma. We show inactivation kinetics for MVM treated with wet-heat (70, 80, 90 degrees C) and with 0.01-1 M NaOH solutions (pH >/=11.9). Robust inactivation was only achieved at 90 degrees C for at least 10 min and in NaOH solutions of pH >/=12.8 (0.1 M NaOH). It was observed, that aggregation of viruses might protect viral particles from inactivation by NaOH. Therefore, appropriate sample preparation of spiking material is important for accurate simulation of the naturally occurring situation. The observed stability at pH 11.8 exceeds the previously reported upper limit of pH 9. Inactivation was due to disintegration of the viral capsid as assessed by accessibility of viral DNA for endonucleases.


Subject(s)
Hot Temperature , Minute Virus of Mice/physiology , Sodium Hydroxide/pharmacology , Virus Inactivation , Animals , Capsid/metabolism , Cell Line , DNA, Viral/metabolism , Humans , Hydrogen-Ion Concentration , Kinetics , Mice , Minute Virus of Mice/drug effects , Minute Virus of Mice/growth & development , Minute Virus of Mice/isolation & purification , Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...